Predicting Biotech Breakouts Before They Happen

 

🚀 Recent ScanScor Breakout Wins

Predicted in advance. No hype. No guesswork. Just AI-powered precision — 15 confirmed breakouts from our first 130 predictions (July 2025).

[ATNF] 180 Life Sciences 1,853%
[EQ] Equillium 493%
[NBY] NovaBay 259%
[MRKR] Marker Thera 158%
[STEM] Stem, Inc 124%
[RIGL] Rigel Pharma 102%
[VSTM] Verastem 72%
[TNXP] Tonix Pharma 56%
[BTAI] BioXcel Thera 325%
[STTK] Shattuck Labs 194%
[VIVS] VivoSim Labs 186%
[IRWD] Ironwood Pharma 79%
[XOMA] XOMA Royalty 55%
[QURE] uniQure N.V 182%
[ATRA] Atara Biother 27%

ScanScor was launched in July 2025. Entry Level access is now only $1.95/month!

Many prediction windows remain open — and others haven’t yet begun. The next breakout could be tomorrow. Join us as we prove the power of AI predictions resulting from thorough screening and carefully crafted prompts.

These results established ScanScor.com

Become a Member

ScanScor enters its next phase in 2026


With over 20 biotech breakouts successfully predicted, the ScanScor platform is rapidly gaining traction among traders seeking early, data-driven insight.

To ensure reliability at scale, we intentionally deferred the launch of Advanced Reports & Scoring while rolling out critical core enhancements that now define ScanScor’s edge:

✅ Breaking News Alerts (Email & Telegram)
Instant notification when meaningful news breaks on tickers with active predictions.

✅ AI-Confirmed Catalyst Alerts (Email & Telegram)
Upon breaking news, alerts are sent only when AI determines the market is likely to react, filtering noise and prioritizing signal.

✅ NDAPR — News-Driven AI Prediction Revision
NDAPR enables ScanScor’s AI to dynamically reevaluate and revise predictions as new information arrives — refining outlooks, adjusting time windows, and adapting in real time as events unfold.

Together, these capabilities are designed to generate a higher-confidence alpha signal, all in pursuit of ever-greater prediction accuracy.

Seats at ScanScor are available for ONLY $1.95/mo! — 397 members and growing.

 

Recent Comments

The ScanScor Prediction Strategy

Step 1 — Detect Catalysts Early

Our Biomed Prediction Engine scans financials, clinical trial data, and news to uncover biotech companies preparing for breakthrough events. These are the moments when stocks often surge.

Step 2 — Define the Investment Window

Each prediction includes a clear time window and target range. This helps you know when a breakout is most likely — and how high it could go.

Step 3 — Track Results and Refine

We publish every prediction and score it after the fact. That way, you can see what worked, what didn’t, and how the system keeps getting sharper over time.

Following the ScanScor strategy is easy as 1, 2, 3

1

Review AI predictions of top biotech candidates.

2

Compare ROI, time windows, and price targets.

3

Use AI summaries, charts, and commentary to act confidently — early.

0

New Predictions Today

3

New Predictions This Month

139

Total Predictions

A Disciplined Screening Process

ScanScor continuously screens hundreds of biotech companies for early signals that often precede major price movement. Only a carefully filtered subset advances to deeper analysis and prediction.

Learn how our screening and prediction process works →

The Biomed Prediction Engine (BPE) is ScanScor’s proprietary AI system, continuously refreshed with live financial, clinical, and news data. We compress relevant data into finely tuned prompts for Orbo, our custom-trained AI model, which generates forward-looking predictions.

Visit regularly to view Orbo’s successful forecasts.  Get a ScanScor Entry Tier Acct for only $1.95/mo and get access to high-potential breakout candidates with current and approaching catalyst windows.

🚀 See what Orbo, the AI behind ScanScor, thinks about our highest-ranked stocks. View the Prediction List
Scroll to Top